IM Cannabis (IMCC) Competitors $3.30 +0.34 (+11.49%) Closing price 07/7/2025 03:59 PM EasternExtended Trading$3.28 -0.01 (-0.45%) As of 07/7/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCC vs. CVKD, CALC, OVID, GBIO, CMMB, ELEV, FGEN, DARE, FNCH, and RLMDShould you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Cadrenal Therapeutics (CVKD), CalciMedica (CALC), Ovid Therapeutics (OVID), Generation Bio (GBIO), Chemomab Therapeutics (CMMB), Elevation Oncology (ELEV), FibroGen (FGEN), Dare Bioscience (DARE), Finch Therapeutics Group (FNCH), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry. IM Cannabis vs. Its Competitors Cadrenal Therapeutics CalciMedica Ovid Therapeutics Generation Bio Chemomab Therapeutics Elevation Oncology FibroGen Dare Bioscience Finch Therapeutics Group Relmada Therapeutics Cadrenal Therapeutics (NASDAQ:CVKD) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability. Which has more risk & volatility, CVKD or IMCC? Cadrenal Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Which has stronger valuation & earnings, CVKD or IMCC? IM Cannabis has higher revenue and earnings than Cadrenal Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadrenal TherapeuticsN/AN/A-$10.65M-$9.26-1.40IM Cannabis$39.44M0.34-$7.72M-$0.64-5.16 Do institutionals & insiders believe in CVKD or IMCC? 7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 48.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer CVKD or IMCC? In the previous week, IM Cannabis had 1 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 1 mentions for IM Cannabis and 0 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score. Company Overall Sentiment Cadrenal Therapeutics Neutral IM Cannabis Neutral Do analysts prefer CVKD or IMCC? Cadrenal Therapeutics currently has a consensus target price of $32.00, suggesting a potential upside of 147.10%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cadrenal Therapeutics is more favorable than IM Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00IM Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CVKD or IMCC more profitable? Cadrenal Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -9.10%. IM Cannabis' return on equity of -122.96% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cadrenal TherapeuticsN/A -244.94% -181.94% IM Cannabis -9.10%-122.96%-11.69% SummaryCadrenal Therapeutics and IM Cannabis tied by winning 7 of the 14 factors compared between the two stocks. Get IM Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCC vs. The Competition Export to ExcelMetricIM CannabisMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.97M$10.52B$5.52B$9.02BDividend YieldN/A2.07%5.24%4.07%P/E Ratio-5.1616.9127.2220.04Price / Sales0.3428.87380.3292.37Price / CashN/A23.9726.2128.59Price / Book3.203.637.945.55Net Income-$7.72M$235.43M$3.17B$248.49M7 Day Performance22.22%-0.32%1.81%4.87%1 Month Performance19.57%-0.33%1.28%6.63%1 Year Performance52.78%-10.48%33.57%20.38% IM Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCCIM Cannabis0.334 of 5 stars$3.30+11.5%N/A+31.3%$11.97M$39.44M-5.16340CVKDCadrenal Therapeutics2.6888 of 5 stars$11.59-3.8%$32.00+176.1%N/A$22.83MN/A-1.254Positive NewsGap UpCALCCalciMedica3.2841 of 5 stars$1.63+1.9%$18.00+1,004.3%-62.0%$22.77MN/A-1.0430Positive NewsGap UpOVIDOvid Therapeutics4.2033 of 5 stars$0.32-3.3%$3.13+879.6%-49.8%$22.76M$570K-0.9160Gap UpHigh Trading VolumeGBIOGeneration Bio2.9431 of 5 stars$0.33+4.0%$7.33+2,102.2%-84.7%$22.32M$19.89M-0.31150News CoverageGap DownCMMBChemomab Therapeutics2.8749 of 5 stars$1.18+1.7%$8.50+620.3%+16.8%$22.26MN/A-1.5520ELEVElevation Oncology1.9004 of 5 stars$0.37+0.2%$3.39+820.0%-86.7%$21.79MN/A-0.4540FGENFibroGen4.7005 of 5 stars$5.33+0.6%$250.00+4,590.4%-70.2%$21.53M$29.62M-2.13570Positive NewsDAREDare Bioscience1.5673 of 5 stars$2.41+0.6%$12.00+399.0%-23.8%$21.28M$10K-14.1530FNCHFinch Therapeutics Group1.0469 of 5 stars$13.20flatN/A+923.6%$21.20M$110K-1.50190Positive NewsRLMDRelmada Therapeutics4.5971 of 5 stars$0.63+5.6%$5.00+688.6%-79.8%$21.04MN/A-0.2510Gap Down Related Companies and Tools Related Companies CVKD Competitors CALC Competitors OVID Competitors GBIO Competitors CMMB Competitors ELEV Competitors FGEN Competitors DARE Competitors FNCH Competitors RLMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCC) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IM Cannabis Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IM Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
